Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight

globenewswire.com
JNJ BIIB Biogen's Litifilimab (BIIB059) is in Phase III trials for SLE, targeting plasmacytoid dendritic cells to reduce pro-inflammatory mediators. Anticipated topline results by late 2026 and its inclusion in a robust pipeline suggest a positive outlook. NVS Novartis' Ianalumab, a BAFF-R targeting monoclonal antibody, is in Phase III trials for SLE. While regulatory filings are anticipated later, its inclusion in the pipeline and ongoing development indicate a positive market outlook. VTRS Viatris is mentioned as a partner in the development of Cenerimod, an S1P1 modulator for SLE. While the drug shows promise, Viatris' specific contribution or direct impact on its stock sentiment is not detailed. RPRX Royalty Pharma is mentioned as a partner in the development of Litifilimab with Biogen. Its role as a financing partner suggests indirect benefit from successful drug development, but direct sentiment impact is not specified. ABBV AZN AstraZeneca is mentioned in relation to Lupus Nephritis and IgA Nephropathy markets, and as a company with pipeline drugs. However, specific details regarding its SLE pipeline are not provided, resulting in a neutral sentiment. MRK Merck KGaA is listed among companies with pipeline drugs for SLE. The article does not provide specific details about their SLE-related pipeline, hence the sentiment is neutral. RIGL Rigel Pharmaceuticals is not explicitly mentioned in the article. The mention of 'BENLYSTA' (belimumab) is associated with GSK, not Rigel. Therefore, no sentiment can be extracted for Rigel. GSK GSK is mentioned in relation to BENLYSTA. While BENLYSTA is approved for SLE, the article focuses on pipeline drugs and future growth, not current performance of approved drugs. Thus, sentiment is neutral. REGN Regeneron Pharmaceuticals is not explicitly mentioned in the article. Therefore, no sentiment can be extracted. GILD Gilead Sciences is not explicitly mentioned in the article. Therefore, no sentiment can be extracted. AMGN Amgen is not explicitly mentioned in the article. Therefore, no sentiment can be extracted. LLY BMY XBI IBB

New York, USA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.

DelveInsight’s Systemic Lupus Erythematosus Market Insights report includes a comprehensive understanding of current treatment practices, emerging systemic lupus erythematosus drugs, market share of individual therapies, and current and forecasted systemic lupus erythematosus market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Systemic Lupus Erythematosus Market Summary

Discover SLE market CAGR and projections to 2034 @ Systemic Lupus Erythematosus Market Report

Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, commented: “The systemic lupus erythematosus market is poised for significant growth over the coming decade, driven by a combination of rising disease prevalence, increased diagnostic awareness, and a robust pipeline of targeted therapies. Additionally, supportive regulatory environments and greater investment in autoimmune disease research are catalyzing market entry of innovative products. These factors collectively suggest that the SLE market will not only grow in terms of revenue but also evolve qualitatively, with more personalized and effective treatment paradigms transforming patient care.”

Key Factors Driving the Growth of the Systemic Lupus Erythematosus Market

Systemic Lupus Erythematosus Market Analysis

Learn more about which therapies will shape the future SLE market @ Systemic Lupus Erythematosus Treatment Market

Systemic Lupus Erythematosus Competitive Landscape

SLE clinical trial landscape possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others in different lines of treatment.

Johnson & Johnson’s Nipocalimab is an investigational monoclonal antibody engineered to selectively and strongly inhibit FcRn, thereby reducing circulating immunoglobulin G (IgG) antibodies while having minimal impact on other innate and adaptive immune functions. By lowering pathogenic autoantibodies and alloantibodies, nipocalimab has potential applications across key autoantibody-driven areas, including rare autoimmune disorders, maternal–fetal diseases caused by maternal alloantibodies, and rheumatic diseases mediated by autoantibodies. In the placenta, FcRn inhibition is also expected to reduce the transfer of maternal alloantibodies to the fetus.

Biogen and Royalty Pharma’s Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody directed against BDCA2 and is under investigation as a potential therapy for systemic lupus erythematosus (SLE). BDCA2 is a receptor selectively expressed on plasmacytoid dendritic cells (pDCs), a specialized subset of immune cells. By binding to BDCA2, litifilimab suppresses pDC activity, leading to reduced secretion of pro-inflammatory mediators, including type I interferons (IFN-I) and other cytokines and chemokines. Biogen is currently evaluating litifilimab in two Phase III clinical studies for SLE, TOPAZ-1 (NCT04895241) and TOPAZ-2 (NCT04961567), with topline results anticipated by the end of 2026.

Novartis’ Ianalumab is a monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R). The therapy is designed to inhibit BAFF-R–dependent signaling pathways while also inducing B-cell depletion via antibody-dependent cellular cytotoxicity. Ianalumab is being assessed in Phase III trials for SLE, including SIRIUS-SLE 1 (NCT05639114) and SIRIUS-SLE 2 (NCT05624749). According to Novartis’ Q3 2025 update, Phase III data are expected in 2027, with regulatory filings now anticipated in 2028 or later.

Idorsia and Viatris’ Cenerimod is a highly selective sphingosine-1-phosphate receptor 1 (S1P1) modulator administered as a once-daily oral therapy. Although the precise etiology of SLE remains unclear, dysregulated T- and B-cell activity is recognized as a central contributor to disease pathogenesis. Cenerimod is currently being evaluated in Phase III trials, OPUS-1 (NCT05648500) and OPUS-2 (NCT05672576), for the treatment of SLE. The U.S. FDA has granted Fast Track Designation to cenerimod for this indication.

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, commented: “The systemic lupus erythematosus clinical trial landscape is increasingly robust, with several mid- to late-stage assets positioning the market for meaningful evolution over the next few years. Nipocalimab’s FcRn inhibition strategy aims to selectively reduce pathogenic IgG autoantibodies, while litifilimab targets plasmacytoid dendritic cell–driven type I interferon signaling, with Phase III readouts expected by late 2026. The anticipated launches of these next-generation therapies are expected to significantly reshape the SLE treatment paradigm, intensifying competition, redefining standards of care, and driving sustained innovation and market expansion in the years ahead.”

The anticipated launch of these emerging SLE therapies are poised to transform the SLE market landscape in the coming years. As these cutting-edge SLE therapies continue to mature and gain regulatory approval, they are expected to reshape the SLE market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about new treatment for SLE, visit @ Systemic Lupus Erythematosus Medication

Recent Developments in the SLE Market

What is Systemic Lupus Erythematosus?

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the body’s immune system mistakenly attacks its own healthy tissues, leading to widespread inflammation and organ damage. It can affect multiple organs and systems, including the skin, joints, kidneys, heart, lungs, blood cells, and nervous system. The disease is characterized by periods of flare-ups and remission, with symptoms varying widely among individuals. Common manifestations include fatigue, joint pain and swelling, skin rashes, fever, and kidney involvement. While the exact cause of SLE is unknown, it is believed to result from a combination of genetic, hormonal, and environmental factors, and it requires long-term management to control symptoms and prevent organ damage.

Systemic Lupus Erythematosus Epidemiology Segmentation

The SLE epidemiology section provides insights into the historical and current systemic lupus erythematosus patient pool and forecasted trends for the leading markets. As per the estimates, in the US, approximately half of the patients suffering from SLE were in moderate severity at the time of diagnosis.

The systemic lupus erythematosus market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

Download the report to understand current treatment standards influencing market share @ Systemic Lupus Erythematosus Treatment Options

Scope of the Systemic Lupus Erythematosus Market Report

Discover more about SLE drugs in development @ Systemic Lupus Erythematosus Clinical Trials

Table of Contents

Related Reports

Systemic Lupus Erythematosus Epidemiology Forecast

Systemic Lupus Erythematosus Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted SLE epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Systemic Lupus Erythematosus Clinical Trial Analysis

Systemic Lupus Erythematosus Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including Roche, Biogen, Viatris Inc., Novartis, Qilu Pharmaceutical, ImmuPharma, Beijing Mabworks Biotech Co., Ltd., Zenas Biopharma, AbbVie, Beijing InnoCare Pharma Tech Co., Ltd., Alumis Inc., Galapagos NV, Palleon Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Johnson & Johnson, Merck KGaA, Resolve Therapeutics, ILTOO Pharma, Argenx, Cartesian Therapeutics, Keymed Biosciences Co., Ltd, BioSenic, Eisai, Vertex Pharmaceuticals, Kyverna Therapeutics, Miltenyi Biomedicine, Astrazeneca, Otsuka Pharmaceutical, Fresh Tracks Therapeutics, among others.

Lupus Nephritis Market

Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including Roche, Novartis, Alexion Pharmaceuticals, AstraZeneca, Cabaletta Bio, AbelZeta, Aurinia Pharmaceuticals, Otsuka Pharmaceuticals, GlaxoSmithKline, among others.

Lupus Nephritis Clinical Trial Analysis

Lupus Nephritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, among others.

IgA Nephropathy Market

IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key IgAN companies including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn| Facebook| Twitter